Average Target Price for Japan Tobacco Increases 7.54%

Market by 2FIRSTS.ai
Dec.18.2023
Average Target Price for Japan Tobacco Increases 7.54%
The average target price for Japan Tobacco has been revised to $23.43, a 7.54% increase since August 1.

According to investment platform Fintel, recent reports have shown that the average one-year target price for Japan Tobacco (OTC:JAPAF) has been revised to $23.43 per share, representing a 7.54% increase from the valuation of $21.78 per share on August 1, 2023.

 

The target price is the average forecast provided by numerous analysts. The latest target price range is from a low of $15.69 per share to a high of $28.92 per share. This average target price represents a decrease of 7.33% from the recent closing price of $25.28 per share.

 

Furthermore, 334 funds or institutions were reported to hold shares of Japan Tobacco, a decrease of 5 or 1.47% from the previous quarter. The average holding ratio of all funds investing in Japan Tobacco was 0.37%, a decrease of 0.21% compared to the previous quarter. The total number of shares held by institutions increased by 0.95% in the past three months to reach 108,634K shares.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai
Belgium seizes 140,019 disposable vapes since the start of 2025 after sales ban took effect
Belgium seizes 140,019 disposable vapes since the start of 2025 after sales ban took effect
Belgium’s Federal Public Health Service said it has seized 140,019 disposable vapes since the start of 2025. The crackdown follows a ban on the sale of disposable e-cigarettes that came into force on January 1.
Dec.31 by 2FIRSTS.ai
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
The U.S. Food and Drug Administration has confirmed that six on! PLUS nicotine pouch products have received Marketing Granted Orders (MGO) through the PMTA pathway. The authorizations were completed under the agency’s nicotine pouch review pilot program in “record time,” with the FDA citing lower levels of harmful constituents while stressing that the decision applies only to the specified products and does not mean they are safe or FDA approved.
Regulations
Dec.20
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11
Buenos Aires Province issues health alert over growing use and promotion of nicotine pouches
Buenos Aires Province issues health alert over growing use and promotion of nicotine pouches
The Ministry of Health of the Province of Buenos Aires issued a health alert to the public and health teams over increased circulation, promotion and consumption of nicotine pouches. It said the disposable oral products dissolve in the mouth without combustion or vapor and are marketed as tobacco-free, but contain nicotine and have a high addictive potential.
Jan.13 by 2FIRSTS.ai
Before the Boom:  Why Manufacturing Is Becoming the Deciding Factor in U.S. Nicotine Pouches — An Interview with Rena World
Before the Boom: Why Manufacturing Is Becoming the Deciding Factor in U.S. Nicotine Pouches — An Interview with Rena World
As the U.S. nicotine pouch market moves toward regulatory clarity and rapid growth, attention is shifting from demand to execution. In an interview with 2Firsts, U.S.-based manufacturer Rena explains why manufacturing capacity, quality systems, and compliance readiness are becoming decisive factors before the market fully takes off.
Jan.19